EyePoint, Inc. EYPT
Updated: 18 Jun 2026
No signal published yet
We already track EyePoint and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow EyePoint, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow EyePoint free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 6, 2026, the company reported a cash position of $223 million, which is expected to fund operations into the fourth quarter of 2027. The company is currently advancing its Phase 3 LUGANO and LUCIA clinical trials for lead candidate DURAVYU in wet AMD, with topline data expected to begin in mid-2026.
What Firelda Watch includes for EyePoint, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow EyePoint, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow EyePoint free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more